Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), VYNE Therapeutics's 3-1 Month Momentum % is 1.53%.
The industry rank for VYNE Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
VYNE's 3-1 Month Momentum % is ranked better than 52.53% of 1382
companies
in the Biotechnology industry
Industry Median: 0.36
vs VYNE: 1.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
VYNE Therapeutics 3-1 Month Momentum % Related Terms
VYNE vs NXTC, LPCN, QNCX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, VYNE Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VYNE Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics (VYNE) has a 3-1 Month Momentum % of 1.53% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on VYNE Therapeutics and its competitors. According to the industry distribution chart, VYNE Therapeutics ranks #656 out of 1382 companies in the Biotechnology industry, placing it in the top 47.5%.
Is VYNE Therapeutics' 3-1 Month Momentum % too high?
VYNE Therapeutics' current 3-1 Month Momentum % is 1.53%. The Biotechnology industry median 3-1 Month Momentum % is 0.36. VYNE Therapeutics' value of 1.53% is 325% above this industry median. Based on the distribution chart, VYNE Therapeutics ranks #656 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VYNE Therapeutics has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does VYNE Therapeutics' 3-1 Month Momentum % compare to NXTC and LPCN?
According to the Biotechnology industry distribution chart, VYNE Therapeutics ranks #656 out of 1382 companies for 3-1 Month Momentum %. This puts VYNE Therapeutics in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.36. VYNE Therapeutics' value of 1.53% is 325% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.36, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VYNE Therapeutics's current 3-1 Month Momentum % of 1.53% is 325% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on VYNE Therapeutics and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VYNE Therapeutics's current 3-1 Month Momentum % is 1.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VYNE Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, VYNE Therapeutics (VYNE) is currently considered Modestly Undervalued. The stock's GF Value™ is $31.61, compared to a current price of $27.86 — trading 11.9% below its estimated fair value. The current 3-1 Month Momentum % is 1.53% and 325% above the Biotechnology industry median of 0.36. VYNE Therapeutics' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For VYNE Therapeutics (VYNE), the current 3-1 Month Momentum % is 1.53% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VYNE Therapeutics (VYNE) Overvalued in 2026?
Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be undervalued.
The current stock price of $27.86 is trading 11.9% below its estimated GF Value™ of $31.61.
GuruFocus considers VYNE Therapeutics to be Modestly Undervalued.
Key valuation signals for VYNE:
3-1 Month Momentum %: 1.53%
GF Value™: $31.61 vs. price of $27.86 (11.9% below fair value)
Industry Position: 325% above the Biotechnology median (#656 of 1382)
No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
41GF Score
Get the complete analysis for VYNE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYNE has been successfully added to your 
